Understand or prevent a condition.
A rescue inhaler that carries an anti-inflammatory steroid alongside the usual airway opener cut severe asthma attacks by 47% in people with mild asthma, compared with the standard albuterol-only inhaler. In the year-long BATURA trial of 2,421 patients, 5.1% of… Read More →
If you've watched a parent's memory fray, you've probably wondered what actually protects an aging brain. A two-year trial in eleven Latin American countries just gave one of the clearest answers yet: among 1,065 adults aged 60 to 77 at… Read More →
Nearly everything proven about the powerful cholesterol-lowering injections called PCSK9 inhibitors came from people who'd already survived a heart attack or stroke. The VESALIUS-CV trial asked whether evolocumab could protect people before that first event, and it did: over a… Read More →
For decades, COPD treatment has meant inhalers, and for many patients the flare-ups kept coming anyway. The 52-week NOTUS trial tested something new: dupilumab, an injectable drug first approved for eczema and asthma, cut COPD flare-ups by 34% in patients… Read More →
Plenty of young people who vape nicotine have tried to stop and discovered how hard that is. In the first placebo-controlled medication trial aimed squarely at them, a familiar quit-smoking pill changed the odds dramatically: 51% of 16-to-25-year-olds taking varenicline… Read More →
Sitting in front of a bright light box each morning nearly doubled the odds of escaping depression. That's the conclusion of a pooled analysis of 11 randomized trials covering 858 adults with depression that had no seasonal pattern: 40.7% of… Read More →
A new heart valve at 82 is meant to be a fresh start. Too often, heart failure circles back within the year. In a Spanish trial of 1,222 patients who had just had an aortic valve replaced through a leg… Read More →
The antiviral so many long COVID patients have pinned hopes on didn't help them. In an NIH trial of 959 adults whose symptoms had dragged on for months, both a 15-day and a 25-day course of Paxlovid left brain fog,… Read More →
Patients starting treatment for metastatic HER2-positive breast cancer stayed ahead of their disease far longer on a newer drug pairing. A trial that enrolled 1,157 patients found trastuzumab deruxtecan plus pertuzumab held the cancer in check for a median of… Read More →
